Stock ANVS ANNOVIS BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Annovis Bio, Inc.

Equities

ANVS

US03615A1088

Market Closed - Nyse
Other stock markets
 21:00:02 13/05/2024 BST 		5-day change 1st Jan Change
6.85 USD +15.51% Intraday chart for Annovis Bio, Inc. +27.09% -63.37%
05-10 Annovis Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
05-09 Annovis Bio, Inc. Announces Unblinding of the Buntanetap Phase III Data in Parkinson?s Disease CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Annovis Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Annovis Bio, Inc. Announces Unblinding of the Buntanetap Phase III Data in Parkinson?s Disease
CI
Sector Update: Health Care Stocks Edge Higher Late Afternoon
MT
Top Midday Decliners
MT
Sector Update: Health Care Stocks Rise in Monday Afternoon Trading
MT
Annovis Bio Shares Tumble After Drug Candidate Buntanetap for Alzheimer's Misses Efficacy Endpoint in Phase 2/3 Study
MT
Annovis Bio reports positive results in mid-stage Alzheimer's treatment trial
RE
Annovis Bio, Inc. Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer?s Disease
CI
Annovis Announces Publication That Supports Understanding of Buntanetap?s Mechanism of Action in Humans
CI
Annovis Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Top Midday Gainers
MT
Annovis Bio, Inc. Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer's Disease
CI
An unknown buyer entered into an agreement to acquire 1.1% stake in Annovis Bio, Inc. for $1 million
CI
North American Morning Briefing : Fed's Preferred -2-
DJ
Annovis Bio, Inc. Announces Last Patient Last Visit in Phase II/III Study of Buntanetap in Alzheimer's Disease
CI
Annovis Bio, Inc. Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company?s Portfolio
CI
Annovis Bio, Inc. Refines Timeline for Parkinson's Phase III Study Data Announcement
CI
Annovis Bio, Inc. Announces Last Patient Last Visit in Phase III Study of Buntanetap in Parkinson?s Disease
CI
Annovis Bio, Inc. Announces Full Enrollment of Its Phase II/III Alzheimer's Disease Trial, Exceeding Original Projects
CI
Annovis Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ANVS Stock
  4. News Annovis Bio, Inc.
  5. Highlights